CN113795262A - 人源化抗dll3嵌合抗原受体及其用途 - Google Patents

人源化抗dll3嵌合抗原受体及其用途 Download PDF

Info

Publication number
CN113795262A
CN113795262A CN202080027518.8A CN202080027518A CN113795262A CN 113795262 A CN113795262 A CN 113795262A CN 202080027518 A CN202080027518 A CN 202080027518A CN 113795262 A CN113795262 A CN 113795262A
Authority
CN
China
Prior art keywords
seq
chain variable
variable region
polypeptide sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080027518.8A
Other languages
English (en)
Chinese (zh)
Inventor
王明晗
邹晖
贾海群
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dongguan Fanshi Biomedical Co ltd
Original Assignee
Dongguan Fanshi Biomedical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dongguan Fanshi Biomedical Co ltd filed Critical Dongguan Fanshi Biomedical Co ltd
Publication of CN113795262A publication Critical patent/CN113795262A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202080027518.8A 2019-04-08 2020-03-30 人源化抗dll3嵌合抗原受体及其用途 Pending CN113795262A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962830598P 2019-04-08 2019-04-08
US62/830,598 2019-04-08
US201962861377P 2019-06-14 2019-06-14
US62/861,377 2019-06-14
US201962896790P 2019-09-06 2019-09-06
US62/896,790 2019-09-06
US201962928615P 2019-10-31 2019-10-31
US62/928,615 2019-10-31
PCT/US2020/025643 WO2020210067A1 (en) 2019-04-08 2020-03-30 Humanized anti-dll3 chimeric antigen receptors and uses thereof

Publications (1)

Publication Number Publication Date
CN113795262A true CN113795262A (zh) 2021-12-14

Family

ID=72750831

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080027518.8A Pending CN113795262A (zh) 2019-04-08 2020-03-30 人源化抗dll3嵌合抗原受体及其用途

Country Status (12)

Country Link
US (1) US20220184127A1 (cg-RX-API-DMAC7.html)
EP (1) EP3952888A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022526420A (cg-RX-API-DMAC7.html)
KR (1) KR20210150432A (cg-RX-API-DMAC7.html)
CN (1) CN113795262A (cg-RX-API-DMAC7.html)
AU (1) AU2020271012A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021016272A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132202A1 (cg-RX-API-DMAC7.html)
IL (1) IL286984A (cg-RX-API-DMAC7.html)
MX (1) MX2021012336A (cg-RX-API-DMAC7.html)
SG (1) SG11202108759SA (cg-RX-API-DMAC7.html)
WO (1) WO2020210067A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114790240A (zh) * 2022-06-10 2022-07-26 郑州大学 SARS-CoV-2中和性单克隆抗体及应用
CN119325484A (zh) * 2023-05-17 2025-01-17 星奕昂(上海)生物科技有限公司 靶向dll3的抗体及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
TWI832183B (zh) * 2019-08-06 2024-02-11 香港商新旭生技股份有限公司 結合至病理性tau種類之抗體及其用途
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
US20240239878A1 (en) * 2021-05-08 2024-07-18 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Binding molecule against dll3 and use thereof
CA3230627A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting dll3 and uses thereof
US20260061051A1 (en) * 2022-08-26 2026-03-05 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
CN120731224A (zh) * 2024-01-30 2025-09-30 石药集团巨石生物制药有限公司 抗dll3抗体及应用
WO2025212519A1 (en) * 2024-04-01 2025-10-09 Moonlight Bio, Inc. Dll3 binding proteins and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011093097A1 (ja) * 2010-01-29 2011-08-04 株式会社未来創薬研究所 抗dll3抗体
WO2013126746A2 (en) * 2012-02-24 2013-08-29 Stem Centrx, Inc. Novel modulators and methods of use
WO2014125273A1 (en) * 2013-02-12 2014-08-21 Oxford Biotherapeutics Limited Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
WO2017021349A1 (en) * 2015-07-31 2017-02-09 Amgen Research (Munich) Gmbh Bispecific antibody constructs binding dll3 and cd3
CN107405362A (zh) * 2015-02-23 2017-11-28 艾伯维施特姆森特克斯有限责任公司 抗dll3嵌合抗原受体及其使用方法
WO2019067805A1 (en) * 2017-09-27 2019-04-04 University Of Southern California NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2664343C (en) * 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
CA2775573A1 (en) * 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
CA2799746C (en) * 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
WO2012019061A2 (en) * 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
JP2014529581A (ja) * 2011-08-05 2014-11-13 イフォム・フォンダツィオーネ・インスティトゥオ・フィルチ・ディ・オンコロジア・モレコラーレ 構成的に活性なuPARバリアントならびに阻害抗体の生成および単離へのそれの使用
CN103173413A (zh) * 2012-12-07 2013-06-26 天津三箭生物技术有限公司 小鼠抗人β-Catenin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
MX2017006167A (es) * 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
AU2019267349B2 (en) * 2018-05-08 2025-06-05 Phanes Therapeutics, Inc. Anti-DLL3 antibodies and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011093097A1 (ja) * 2010-01-29 2011-08-04 株式会社未来創薬研究所 抗dll3抗体
WO2013126746A2 (en) * 2012-02-24 2013-08-29 Stem Centrx, Inc. Novel modulators and methods of use
WO2014125273A1 (en) * 2013-02-12 2014-08-21 Oxford Biotherapeutics Limited Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
CN107405362A (zh) * 2015-02-23 2017-11-28 艾伯维施特姆森特克斯有限责任公司 抗dll3嵌合抗原受体及其使用方法
WO2017021349A1 (en) * 2015-07-31 2017-02-09 Amgen Research (Munich) Gmbh Bispecific antibody constructs binding dll3 and cd3
WO2019067805A1 (en) * 2017-09-27 2019-04-04 University Of Southern California NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114790240A (zh) * 2022-06-10 2022-07-26 郑州大学 SARS-CoV-2中和性单克隆抗体及应用
CN114790240B (zh) * 2022-06-10 2023-06-06 郑州大学 SARS-CoV-2中和性单克隆抗体及应用
CN119325484A (zh) * 2023-05-17 2025-01-17 星奕昂(上海)生物科技有限公司 靶向dll3的抗体及其应用

Also Published As

Publication number Publication date
CA3132202A1 (en) 2020-10-15
AU2020271012A1 (en) 2021-09-09
JP2022526420A (ja) 2022-05-24
WO2020210067A1 (en) 2020-10-15
MX2021012336A (es) 2021-11-12
IL286984A (en) 2021-12-01
US20220184127A1 (en) 2022-06-16
EP3952888A1 (en) 2022-02-16
SG11202108759SA (en) 2021-10-28
KR20210150432A (ko) 2021-12-10
BR112021016272A2 (pt) 2021-11-09

Similar Documents

Publication Publication Date Title
CN113784980B (zh) 人源化抗Claudin18.2嵌合抗原受体及其用途
US20220184127A1 (en) Humanized anti-dll3 chimeric antigen receptors and uses thereof
TWI755547B (zh) 靶向表皮生長因子受體變異體iii之嵌合型抗原受體
CN113728007B (zh) 人源化抗叶酸受体1嵌合抗原受体及其用途
CN119095879A (zh) 抗间皮素抗体及其用途
EP4146702A2 (en) Anti-tumor associated antigen antibodies and uses thereof
US20220305056A1 (en) Chimeric antigen receptor system and uses thereof
HK40056381A (en) Humanized anti-dll3 chimeric antigen receptors and uses thereof
US20250136703A1 (en) Anti-il13ra2 antibodies and uses thereof
HK40056036A (en) Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof
HK40056378A (en) Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
WO2025147472A1 (en) Anti-611-ctf p95her2 antibodies and uses thereof
HK40056378B (en) Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
WO2024076864A2 (en) Anti-ror1 antibodies and uses thereof
WO2024091870A2 (en) Anti-egfrviii antibodies and uses thereof
HK40085458A (en) Anti-tumor associated antigen antibodies and uses thereof
WO2024182475A2 (en) Anti-ror2 antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40056381

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211214

WD01 Invention patent application deemed withdrawn after publication